Abstract
A 30-year-old woman presented with a right breast tumor. Mucinous carcinoma was diagnosed by core needle biopsy (T2: 5 cm N1 M0). Despite receiving a neoadjuvant anthracycline and taxane regimen, the patient demonstrated no clinical response (NC). Based on the patient’s strong preference, we performed breast-conserving surgery. On histological examination, we observed widespread mucus and a few viable malignant cells, a Grade 2 therapeutic response. Neither optimal management procedures nor guidelines for chemotherapy for primary mucinous carcinoma of the breast have been established. It is a reasonable assumption, however, that discordance between the clinical response and therapeutic response to neoadjuvant chemotherapy may occur in cases of mucinous carcinoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Akashi-Tanaka S, Fukutomi T, Watanabe T,et at: Accuracy of contrast-enhanced computed tomography in the prediction of residual breast cancer after neoadjuvant chemotherapy.Int J Cancer (Radiat Oncol Invest) 96:66–73, 2001.
Akashi-Tanaka S, Fukuotmi T, Sato N,et at: The use of contrast-enhanced computed tomography before neoadjuvant chemotherapy to identify patients likely to be treated safely with breast-conserving surgery.Ann Surg 239:238–243, 2004.
The Japanese Breast Cancer Society: General rules for clinical and pathological recording of breast cancer, 14th ed. Kanehara, Tokyo, 2000.
Andre S, Cunha F, Bernardo M,et at: Mucinous carcinoma of the breast: a pathological study of 82 cases.J Surg Oncol 58:162–167, 1995.
Ian K. Komenaka, Mahmoud B. El-Tamer,et at: Pure mucinous carcinoma of the breast.Am J Surg 187:528–532, 2004.
Anan K, Mitsuyama S, Tanaka K,et at: Pathological features of mucinous carcinoma of the breast are favorable for breast-conserving therapy.EJSO 27:459–463, 2001.
Henry M. Kuerer, Lisa A. Newman, Terry L. Smith,et at: Clinical course of breast cancer patients with complete pathologic primary tumor and lymph node response to doxorubicin-based neoadjuvant chemotherapy.J Clin Oncol 17:460–469, 1999.
AH Honkoop, PJ van Diest, JS de Jong,et at Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer.British J Cancer 77:621–626, 1998.
Frederique Penault-llorca, Anne Cayre, Florence Bouchet Mishellany,et at: Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome.IntJ Oncol 22:1319–1325, 2003.
Nakamura T, Fukutomi T, Tsuda H,et at: Changes in findings of mammography, ultrasonography and contrast-enhanced computed tomography of three histological complete responders with primary breast cancer before and after neoadjuvant chemotherapy: case reports.Jpn J Clin Oncol 30:453–457, 2000.
Edwin R, Fisher, Jiping Wang, John Bryant,et at: Pathobiology of preoparative chemotherapy. Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-18.Cancer 95:681–694, 2002.
Radhika Rajan, Anna Poniecka, Terry L. Smith,et at: Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response.Cancer 100:1365–1373, 2004.
Author information
Authors and Affiliations
About this article
Cite this article
Yamaguchi, J., Akashi-Tanaka, S., Fukutomi, T. et al. A case of mucinous carcinoma of the breast that demonstrated a good pathological response to neoadjuvant chemotherapy despite a poor clinical response. Breast Cancer 13, 100–103 (2006). https://doi.org/10.2325/jbcs.13.100
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.2325/jbcs.13.100